Success Metrics

Completion Rate

0%(0/2)

Active Trials

0(0%)

Terminated

2(67%)

Phase Distribution

Ph phase_3

33%

Ph phase_4

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

1(33.3%)

Phase 4Post-market surveillance

2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(2)

Other(1)

Detailed Status

Terminated2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (33.3%)

Phase 42 (66.7%)

Trials by Status

unknown133%

terminated267%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_3

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

NCT02247687

unknownphase_4

Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)

NCT01230580

terminatedphase_4

Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients

NCT00122668

Clinical Trials (3)

Showing 3 of 3 trials

NCT02247687Phase 3

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Terminated

NCT01230580Phase 4

Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)

Unknown

NCT00122668Phase 4

Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3